Therapeutic Advances in Psychopharmacology最新文献

{"title":"Impact of <i>CYP1A</i>, <i>CYP2C19</i>, <i>CYP2D6</i>, <i>CYP3A4</i>, <i>CYP3A5</i>, and <i>NFIB</i> genotypes on clozapine serum concentration in smokers and nonsmokers.","authors":"Hasan Çağın Lenk, Line Skute Bråten, Ole A Andreassen, Espen Molden","doi":"10.1177/20451253251377183","DOIUrl":"10.1177/20451253251377183","url":null,"abstract":"<p><strong>Background: </strong>Clozapine is the most effective drug for schizophrenia and is the only drug indicated for use in patients with treatment resistance. The therapeutic range of clozapine is narrow with extensive interindividual differences in serum levels at similar dosing, mainly due to variability in hepatic metabolism mediated by several cytochrome P450 (CYP) enzymes. Tobacco smoking is the most important environmental factor determining clozapine metabolism, while the effect of pharmacogenetic variability is unclear.</p><p><strong>Objectives: </strong>To investigate the impact of <i>CYP1A, CYP2C19, CYP2D6, CYP3A4, CYP3A5</i>, and <i>NFIB</i> alleles on clozapine levels stratified by smoking status in a large patient population.</p><p><strong>Design: </strong>This is a retrospective naturalistic/observational study.</p><p><strong>Methods: </strong>The study population was included from the therapeutic drug monitoring/pharmacogenetics service at the Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway, during January 2005-November 2024. We assessed the influence of <i>CYP1A</i> rs247229 <i>T</i>, <i>CYP1A2*1F</i>, <i>CYP2C19</i>, <i>CYP2D6</i>, <i>CYP3A4*22</i> and <i>CYP3A5*3</i>, and <i>NFIB</i> rs28379954 <i>C</i> genetic variants on clozapine dose-adjusted serum concentrations (CD) in both smokers and nonsmokers.</p><p><strong>Results: </strong>The study comprised 663 participants (55% smokers). <i>CYP1A T</i> variant was significantly associated with reduced clozapine serum levels, compared to <i>CYP1A CC</i> genotype, both among smokers (-15%, <i>p</i> = 0.010) and nonsmokers (-16%; <i>p</i> = 0.011). Moreover, among smokers, participants with <i>NFIB C</i> variant had 40% reduced clozapine CD compared to participants with <i>NFIB TT</i> (<i>p</i> < 0.001), whereas carriers of the <i>CYP3A5*1/*1</i> genotype exhibited a 37% lower clozapine CD compared to <i>CYP3A5*3/*3</i> carriers (<i>p</i> = 0.024) among nonsmokers. <i>CYP1A2*1F</i>, <i>CYP2C19</i>, <i>CYP2D6</i>, and <i>CYP3A4*22</i> variants did not have any significant impact on clozapine CD, regardless of smoking habits.</p><p><strong>Conclusion: </strong>The <i>CYP1A T</i>, <i>NFIB C</i>, and <i>CYP3A5*1</i> alleles have significant impact on clozapine serum levels. Incorporating genotype information for these variants, together with patient smoking status, would improve algorithms for precision dosing of clozapine.</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"15 ","pages":"20451253251377183"},"PeriodicalIF":4.0,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12496473/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145239765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychedelic-assisted therapy as a complex intervention: implications for clinical trial design.","authors":"S D Muthumaraswamy, M J Baggott, E E Schenberg, D Repantis, M Wolff, A Forsyth, T Noorani","doi":"10.1177/20451253251381074","DOIUrl":"10.1177/20451253251381074","url":null,"abstract":"<p><p>Psychedelic-assisted therapy (PAT) has typically been evaluated using conventional randomised controlled trials (RCTs), which assess treatment efficacy under highly controlled conditions. However, PAT constitutes a complex intervention, integrating pharmacological, psychotherapeutic and contextual elements that interact dynamically with patient experiences and healthcare settings. Conventional RCTs, designed for simple interventions, may fail to capture these complexities. Pragmatic trials, by contrast, evaluate interventions under real-world conditions, assessing their effectiveness across diverse clinical environments and patient populations. This position paper advocates for the application of the UK Medical Research Council's (MRC) framework for complex interventions to the development and evaluation of PAT. This framework emphasises the necessity of articulating the underlying theory of therapeutic change, structuring intervention development into defined phases, accounting for contextual interactions and incorporating stakeholder perspectives throughout the research process. We argue that employing pragmatic trial designs, guided by the PRECIS-2 tool, will better align PAT research with the practicalities of healthcare delivery and facilitate the translation of research findings into clinical practice. Further, we address the philosophical divergence in the field between conceptualising PAT as primarily pharmacological versus psychotherapy-augmented, noting the implications of these positions for trial design and interpretation. We propose the integration of qualitative methodologies, adaptive trial designs and comparative effectiveness research to refine PAT interventions and address limitations inherent in conventional double-blind RCT approaches. Finally, we advocate for a pluralistic evidentiary model, combining academic and community-led research, to support the rigorous, equitable and sustainable development of psychedelic-assisted therapies and to avoid the historical setbacks that previously hindered progress in this field.</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"15 ","pages":"20451253251381074"},"PeriodicalIF":4.0,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12491819/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145233447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psilocybin with psychotherapeutic support for treatment-resistant depression: a pilot clinical trial.","authors":"Sally Meikle, Olivia Carter, Paul Liknaitzky, Lauren Johansen, Ravi Iyer, Nigel Strauss, Martin Williams, David Castle, Susan L Rossell","doi":"10.1177/20451253251377187","DOIUrl":"10.1177/20451253251377187","url":null,"abstract":"<p><strong>Background: </strong>Depressive disorders are a major global health challenge, with many individuals unresponsive to existing treatments. Novel psychedelic therapies show promise but require further research.</p><p><strong>Objectives: </strong>This study aimed to evaluate the feasibility, safety and effectiveness of psilocybin with psychotherapeutic support for treatment-resistant depression (TRD), investigate predictors of treatment outcomes and deepen understanding of individual variability in response.</p><p><strong>Design: </strong>Open-label, single-arm pilot trial with mixed-methods assessment.</p><p><strong>Methods: </strong>Treatment consisted of two 25 mg psilocybin sessions, alongside three preparatory and six integration sessions. Depression severity was assessed using the self-rated Quick Inventory of Depressive Symptomatology at 3 weeks (primary endpoint) and at 20 weeks post-dose 2 (long-term follow-up). Potential predictors of clinical outcomes were evaluated using questionnaires, and qualitative interviews were used to capture individual experiences.</p><p><strong>Results: </strong>At the aggregate level, a clinically meaningful reduction in depressive symptoms was observed at the primary endpoint (mean change = -7.14; <i>p</i> = 0.02; Hedges' g = -1.27; 95% CI [-2.40, -0.37]) and maintained long-term. Individual participant data revealed diverse response patterns. Two participants displayed a sustained treatment response, three relapsed, and two exhibited no substantial improvement. Exploratory analyses identified mindset prior to dosing, spiritual experiences and perceptual shifts during dosing as predictors of treatment trajectory, while treatment expectations were not a reliable predictor. Adverse events were largely consistent with previous studies, with no serious adverse events.</p><p><strong>Conclusion: </strong>Findings add to the growing evidence base for psilocybin therapy and provide direction for further research on individual variability in response to better tailor treatments and enhance efficacy.</p><p><strong>Trial registration: </strong>Australian New Zealand Clinical Trials Registry (ACTRN12621001097831).</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"15 ","pages":"20451253251377187"},"PeriodicalIF":4.0,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12491823/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145233453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of intraoperative ketamine/esketamine in the prevention of postoperative delirium: a systematic review and meta-analysis.","authors":"Chengchuan Chen, Na Zhou, Jixin Hou","doi":"10.1177/20451253251339378","DOIUrl":"10.1177/20451253251339378","url":null,"abstract":"<p><strong>Background: </strong>Postoperative delirium (POD) is associated with higher risks of postoperative complications ‌and‌ mortality (2- to 3-fold increase). Studies investigating the effect of intraoperative ketamine on POD risk have yielded conflicting results. This study aimed to assess the effects of intraoperative ketamine and its more potent version, esketamine, on POD.</p><p><strong>Design: </strong>Systematic review and meta-analysis.</p><p><strong>Objective: </strong>To evaluate the effect of intraoperative ketamine/esketamine on the incidence of POD.</p><p><strong>Methods: </strong>We adhered to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, and searched the PubMed, Embase, Medline (Ovid), Cochrane, Scopus, and Web of Science databases for the MeSH terms \"ketamine\" and \"emergence delirium\" from database inception to July 10, 2024. The primary outcome was POD incidence following general anesthesia. Data were analyzed using a common effects model, with between-study heterogeneity tested using the <i>I</i> ² statistic, and relative risk (RR) with 95% confidence intervals (CIs) for dichotomous data was used as the effect measure.</p><p><strong>Results: </strong>A total of 18 studies with a total of 1571 participants met eligibility criteria. A meta-analysis of all studies suggests that the intraoperative use of ketamine/esketamine may reduce the incidence of POD (RR = 0.71, 95% CI: 0.56, 0.90, <i>p</i> < 0.01). In the drug subgroup, esketamine demonstrated enhanced efficacy in preventing POD compared to ketamine (RR = 0.59, 95% CI: 0.38, 0.90, <i>p</i> = 0.02). In addition, subanesthetic doses of ketamine/esketamine (⩽0.5 mg/kg) contributed to POD prevention (RR = 0.52, 95% CI: 0.34, 0.79, <i>p</i> < 0.01), whereas higher doses (>0.5 mg/kg) showed no statistically significant effect (RR = 0.89, 95% CI: 0.66, 1.21, <i>p</i> = 0.46). Further analysis revealed additional benefits of ketamine/esketamine in reducing POD incidence in cardiac surgery (RR = 0.46, 95% CI: 0.31, 0.68, <i>p</i> < 0.01), in the elderly (RR = 0.68, 95% CI: 0.52, 0.91, <i>p</i> < 0.01), and in the first 24 h post-surgery (RR = 0.52, 95% CI: 0.29, 0.94, <i>p</i> = 0.03).</p><p><strong>Conclusion: </strong>Our findings suggest that perioperative administration of ketamine/esketamine had a protective effect against the incidence of POD, with esketamine demonstrating superior efficacy compared to ketamine. The treatment effect exhibited a dose-response relationship, with subanesthetic doses showing greater efficacy. Furthermore, ketamine/esketamine may offer additional benefits for patients with specific risk factors.</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"15 ","pages":"20451253251339378"},"PeriodicalIF":4.0,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12450268/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145125842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of long-acting injectable antipsychotics in an acute inpatient psychiatric unit and 90-day re-hospitalization rates: results of an observational prospective study.","authors":"Claudio Brasso, Anna Maria Beoni, Gianluca Colli, Giulia Nicoletta Mariani, Paola Rocca","doi":"10.1177/20451253251367591","DOIUrl":"10.1177/20451253251367591","url":null,"abstract":"<p><strong>Background: </strong>Poor adherence to antipsychotic medications is the leading cause of relapses and hospitalizations in patients with schizophrenia, resulting in worse functional outcomes and quality of life. Long-acting injectable (LAI) antipsychotics are an effective therapeutic option to improve adherence, but they are often underutilized, particularly during inpatient care.</p><p><strong>Objective: </strong>To investigate the predictive factors for LAI utilization among inpatients with schizophrenia and to assess whether initiating a LAI antipsychotic treatment during hospitalization reduces the risk of readmission.</p><p><strong>Design: </strong>Observational prospective study.</p><p><strong>Methods: </strong>Patients were evaluated at admission, discharge, and after 3 months. Two comparisons were performed: patients who initiated a LAI during the hospitalization versus those who continued with oral antipsychotics, and readmitted versus not-readmitted patients within 3 months. Factors statistically associated with LAI initiation or readmission were entered as independent variables in two backward logistic regression models, having \"LAI initiation\" and \"rehospitalization at three months\" as outcomes.</p><p><strong>Results: </strong>One hundred two patients were included. Twelve were lost at follow-up. Forty-two (44%) initiated an LAI during the admission. Subjects who received LAI were significantly younger, more educated, and less adherent to treatment. Thirty (33%) patients were readmitted within 3 months after discharge. Re-hospitalized subjects had more psychiatric hospitalizations in the past and a lower rate of LAI antipsychotic treatment initiation during the studied hospitalization: 5/39 (13%) patients prescribed a LAI antipsychotic were readmitted within 3 months, compared with 25/51 (49%) prescribed an oral antipsychotic medication (OR = 0.19; <i>p</i> = 0.002).</p><p><strong>Conclusion: </strong>Introducing LAI antipsychotic treatment during a psychiatric hospitalization may reduce the risk of early readmissions, thus facilitating the improvement of the course of the illness and the patient's quality of life.</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"15 ","pages":"20451253251367591"},"PeriodicalIF":4.0,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12420969/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145041298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of psilocybin therapy on suicidal ideation, attempts, and deaths in people with psychiatric diagnoses: a systematic review and meta-analysis.","authors":"Stanley Wong, Gray Meckling, Nicholas Fabiano, Sanghun Lee, Brett D M Jones, Risa Shorr, Aroldo Dargel, Alan K Davis, Jess G Fiedorowicz, Marco Solmi, Joshua D Rosenblat, Benoit H Mulsant, Daniel M Blumberger, Muhammad Ishrat Husain","doi":"10.1177/20451253251372449","DOIUrl":"10.1177/20451253251372449","url":null,"abstract":"<p><strong>Background: </strong>Suicidal ideation, attempts, and deaths present a major and tragic public health concern. Recent trials of psilocybin therapy (PT) have shown promise in treating treatment-resistant depression and have found a reduction in suicidal ideation. Given the growth of PT research, there is a need to further understand its effect on suicidal ideation, attempts, and deaths.</p><p><strong>Objective: </strong>To assess and synthesize evidence on the effects of PT on suicidal ideation, attempts, and deaths in psychiatric patients.</p><p><strong>Design: </strong>PRISMA-compliant systematic review and meta-analysis.</p><p><strong>Data source: </strong>MEDLINE, EMBASE, Cochrane, and PsychINFO.</p><p><strong>Method: </strong>Databases were searched for randomized controlled trials of PT in adults with psychiatric diagnoses that reported suicide outcomes (ideation, attempts, and deaths). Abstract and full-text screening were conducted, and suicide outcomes were extracted. Meta-analysis was performed with a random effects model to assess changes in suicide outcomes compared to control through the standardized mean difference (SMD). Assessment of heterogeneity, risk of bias, and subgroup analysis was completed.</p><p><strong>Results: </strong>Nine studies were included (<i>N</i> = 593; 335 psilocybin & 258 control). Two studies were excluded from meta-analysis because suicide-related outcomes data were not available. Participants with PT experienced a small and significant decrease in suicidal ideation compared to control (<i>k</i> = 7, SMD = -0.24, 95% CI -0.42 to -0.06, <i>p</i> = 0.008, <i>I</i> ² = 0%). There was no publication bias found. Subgroup analysis found no significant differences between groups. No study reported suicide attempts or suicide deaths. Two studies had a high risk of bias.</p><p><strong>Conclusion: </strong>Psilocybin therapy may reduce suicidal ideation in adults with psychiatric diagnoses. Current studies are limited by small sample size, lack of follow-up data, and assessment of blinding.</p><p><strong>Trial registration: </strong>CRD42023445706.</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"15 ","pages":"20451253251372449"},"PeriodicalIF":4.0,"publicationDate":"2025-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12417673/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145041226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frequency of anticholinergic drug use in patients treated with aripiprazole once-monthly: a 2-year cohort study using European healthcare databases.","authors":"Frank Andersohn, Pedro Such, Michael Jan, Uwa Kalu, Jessica McDonough, Jonas Reinold, Oliver Riedel, Gianluca Trifirò, Valentina Ientile, Michele Tari, Maurizio Pastorello, Alejandro Arana, Joan Forns, Katja M Hakkarainen, Leyla Nunez, Kristian Tore Jørgensen, Jacob Simonsen, Murat Yildirim","doi":"10.1177/20451253251368010","DOIUrl":"10.1177/20451253251368010","url":null,"abstract":"<p><strong>Background: </strong>Extrapyramidal symptoms (EPS) in association with the long-acting, injectable, atypical antipsychotic aripiprazole once monthly (AOM) have been observed in clinical trials, but information on EPS requiring treatment with anticholinergic drugs in clinical practice is limited.</p><p><strong>Objectives: </strong>The objective of this European post-authorisation safety study (PASS) was to assess the risk of EPS-related events, as defined by dispensings of anticholinergic drugs, linked to the use of AOM in routine clinical practice.</p><p><strong>Design: </strong>This European cohort study was based on healthcare databases from Germany (German Pharmacoepidemiological Research Database GePaRD), Italy (Caserta and Palermo healthcare claims databases), and Sweden (National health registers). New users of AOM were followed from their first dispensing for a maximum of 2 years.</p><p><strong>Methods: </strong>Primary study outcome was an EPS-related event, defined as the first dispensing of an anticholinergic drug. The crude incidence rate (IR) and the cumulative incidence of EPS-related events were estimated. Cox proportional hazard regression modelling was performed to further investigate the effect of potential risk factors for the occurrence of EPS-related events.</p><p><strong>Results: </strong>A total of <i>N</i> = 1748 patients were eligible for inclusion into the primary study populations (Germany <i>N</i> = 629; Italy <i>N</i> = 519; Sweden <i>N</i> = 600). IRs of EPS-related events per 100 patient years were highest in Italy (IR = 18.4; 95% confidence interval (CI) 15.3-22.1), followed by Sweden (IR = 7.7; 95% CI 5.8-10.2) and Germany (IR = 3.4; 95% CI 2.4-4.6). Rates were highest during the first 30 days after treatment initiation. Cumulative incidences after 2 years of treatment were 27.8% (Italy), 11.5% (Sweden), and 10.0% (Germany). Diabetes and previous antipsychotic drug use were identified as risk factors for EPS-related events.</p><p><strong>Conclusion: </strong>In this observational study, incidence rates of EPS-related events, defined as the first dispensing of an anticholinergic drug during follow-up, were compatible with the known safety profile of AOM but showed substantial regional variation.</p><p><strong>Trial registration: </strong>EU PAS number EUPAS21056.</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"15 ","pages":"20451253251368010"},"PeriodicalIF":4.0,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12398657/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144970260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of long-acting injectable antipsychotics on treatment adherence and healthcare utilization in Chinese patients with schizophrenia: a mirror-image study.","authors":"Lei Zhang, Tao Wu, Jingwen Li, Chengxiang Du, Rui Chi, Kun Jiang, Hong Qiu, Yea-Jen Hsu, Wentian Dong, Huaning Wang, Tianmei Si","doi":"10.1177/20451253251360400","DOIUrl":"10.1177/20451253251360400","url":null,"abstract":"<p><strong>Background: </strong>Long-acting injectable (LAI) antipsychotics can improve treatment adherence in patients with schizophrenia. Despite their benefits, LAIs are underused in China compared to other countries. Little real-world evidence describes the impact of switching from oral to LAI antipsychotics on adherence and healthcare utilization in clinical practice in China, which could help address this gap.</p><p><strong>Objectives: </strong>To understand utilization of LAI and to assess the impact of switching from oral to LAI antipsychotics on adherence and healthcare utilization.</p><p><strong>Design: </strong>This is a retrospective, 1-year mirror-image study using electronic health records (2012-2019) from a psychiatric specialized hospital and the psychiatry department in a general hospital in China. The observation period was 1 year before and after LAI initiation in patients already receiving oral antipsychotics.</p><p><strong>Methods: </strong>Adult patients (aged 18-65) who initiated LAIs after receiving oral antipsychotics, with schizophrenia diagnosis at least 12 months before LAI initiation were included. The date of LAI initiation was designated as the index date. Adherence to antipsychotics was assessed by the proportion of days covered. Schizophrenia-related healthcare utilization comprised the percentage of patients who had admissions, the duration of inpatient stays, the number of inpatient visits, and outpatient visits. Wilcoxon signed-rank test and McNemar's test were used for before-after comparison.</p><p><strong>Results: </strong>Overall, 98 and 59 eligible patients were included in two hospitals, respectively. Treatment adherence (proportion of days covered) after switching increased significantly from 46% to 61% (<i>p</i> < 0.01) and 32% to 58% (<i>p</i> < 0.01), respectively. The frequency of hospital admissions (and cumulative admission days) reduced from 10.2% to 4.1% (6 days to 2 days, <i>p</i> = 0.11), and 55.9% to 10.2% (11 days to 2 days, <i>p</i> < 0.01), respectively. Outpatient visits increased from 5 to 6 visits (<i>p</i> = 0.10), and 7 to 9 visits (<i>p</i> < 0.01), respectively.</p><p><strong>Conclusion: </strong>Consistent benefits of LAIs in enhancing treatment adherence and optimizing healthcare utilization were observed in two representative hospitals having different clinical settings and patient characteristics.</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"15 ","pages":"20451253251360400"},"PeriodicalIF":4.0,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12374043/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144970343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ketamine-assisted therapy within a community of practice: a novel approach to disordered eating.","authors":"Lara Jeletzky, Shannon Dames, Pamela Kryskow, Vivian W L Tsang","doi":"10.1177/20451253251356980","DOIUrl":"10.1177/20451253251356980","url":null,"abstract":"","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"15 ","pages":"20451253251356980"},"PeriodicalIF":3.4,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12260326/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144643638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacotherapy for post-traumatic stress disorder: systematic review and meta-analysis.","authors":"Yanyan Jia, Zifeng Ye, Fude Yang, Jiabao Chai, Haiting Xu, Jingming Yang, Weiye Liang, Lili Wu","doi":"10.1177/20451253251342628","DOIUrl":"10.1177/20451253251342628","url":null,"abstract":"<p><strong>Background: </strong>Post-traumatic stress disorder (PTSD) is a prevalent mental illness with a high disability rate. The neurobiological abnormalities in PTSD suggest that drug therapy may have certain therapeutic effects. According to the recommendations of clinical guidelines for PTSD, the current clinical preference is for selective serotonin reuptake inhibitors (SSRIs) or serotonin and norepinephrine reuptake inhibitors (SNRIs). Nevertheless, the efficacy of other types of drugs remains uncertain, which impacts the selection of personalized treatment for patients.</p><p><strong>Objectives: </strong>The aim of this meta-analysis was to assess the efficacy and acceptability of drugs with different pharmacological mechanisms in alleviating PTSD symptoms by comparing the response rates and dropout rates of different drug treatment groups in randomized clinical trials.</p><p><strong>Design: </strong>Systematic review and meta-analysis.</p><p><strong>Methods: </strong>We searched and analyzed 52 reports that described the efficacy and acceptability of medication for PTSD. Among these, 49 trials used the dropout rate as an acceptability indicator, and 52 trials used the response rate as an efficacy indicator.</p><p><strong>Results: </strong>In the 49 trials with the dropout rate as the indicator, the dropout rate was 29% (95% confidence interval, 0.26-0.33; <i>n</i> = 3870). In the 52 trials with the response rate as the indicator, the response rate was 39% (95% confidence interval, 0.33-0.45; <i>n</i> = 3808). After drug treatment, the core symptoms of PTSD were significantly improved. This meta-analysis indicated that there was no significant difference between antidepressants and antipsychotics in improving clinical symptoms and acceptability. However, antidepressants may have a slight advantage in efficacy, although with a higher dropout rate.</p><p><strong>Conclusion: </strong>Drug treatment is an effective rehabilitation method for PTSD patients, and individualized drug management should be considered.</p><p><strong>Trial registration: </strong>This systematic evaluation scheme has been registered with PROSPERO (protocol ID: CRD42023462662).</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"15 ","pages":"20451253251342628"},"PeriodicalIF":3.4,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12171264/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144317919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}